Online citations, reference lists, and bibliographies.

Continuous Infusion Of Beta-lactam Antibiotics

A. Muller, J. Mouton
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
For beta-lactam antibiotics continuous infusion can be used to optimise antibiotic therapy. Pre-clinical studies in rodents and in vitro studies have shown the benefits of continuous infusion when compared to intermittent dosing. Pharmacokinetic studies in humans have shown an improved probability of target attainment for continuous infusion. However, the relationship between continuous infusion and improved clinical outcome is ambiguous. The superiority of continuous infusion over intermittent dosing in clinical outcome studies is most often documented in special subgroups, such as critically ill patients or patients infected with less-susceptible micro-organisms. Methods to calculate doses during continuous infusion and practical issues, such as stability of antimicrobial solutions, are described.
This paper references
10.1128/AAC.49.8.3550-3553.2005
Ceftazidime in Acute Myeloid Leukemia Patients with Febrile Neutropenia: Helpfulness of Continuous Intravenous Infusion in Maximizing Pharmacodynamic Exposure
F. Pea (2005)
10.1016/S0002-9610(05)80507-0
Continuous infusion of cefazolin is superior to intermittent dosing in decreasing infection after hemorrhagic shock.
D. Livingston (1993)
10.1016/j.jtcvs.2010.03.038
Cefazolin bolus and continuous administration for elective cardiac surgery: improved pharmacokinetic and pharmacodynamic parameters.
C. Adembri (2010)
10.1097/00007691-199902000-00010
Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis.
N. A. van Lent-Evers (1999)
10.1002/jhm.869
Use of pharmacodynamic principles to inform β-lactam dosing: "S" does not always mean success.
Thomas P Lodise (2011)
10.1007/s00134-006-0401-5
Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia
E. Boselli (2006)
10.1016/j.ijantimicag.2008.07.010
In vivo efficacy of humanised intermittent versus continuous ceftazidime in combination with tobramycin in an experimental model of pseudomonal pneumonia.
D. Croisier (2008)
10.1007/BF01725189
Adverse reactions following intravenous penicillin-G relate to degradation of the drug in vitro
K. Neftel (2005)
10.1086/422002
The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens.
C. Donskey (2004)
10.1097/01.CCM.0000098031.24329.10
Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis*
J. Garnacho-Montero (2003)
10.1016/S0002-9610(00)00388-3
Intermittent and continuous ceftazidime infusion for critically ill trauma patients.
S. Hanes (2000)
10.1128/AAC.39.8.1797
Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
D. Cappelletty (1995)
10.1093/infdis/152.2.373
Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats.
R. Roosendaal (1985)
10.1093/jac/dkp139
Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
J. Roberts (2009)
10.5414/CPP43360
Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen.
B. Georges (2005)
10.1016/J.IJANTIMICAG.2006.10.018
Continuous-infusion penicillin home-based therapy for serious infections due to penicillin-susceptible pathogens.
A. Walton (2007)
Letter: Doctors in Chile.
T. Heller (1974)
10.1128/AAC.46.8.2327-2332.2002
Comparative Stability Studies of Antipseudomonal β-Lactams for Potential Administration through Portable Elastomeric Pumps (Home Therapy for Cystic Fibrosis Patients) and Motor-Operated Syringes (Intensive Care Units)
E. Viaene (2002)
10.1093/jac/dkq044
Stability of meropenem and doripenem solutions for administration by continuous infusion.
K. Berthoin (2010)
10.1128/AAC.35.1.57
Aztreonam pharmacokinetics in burn patients.
L. Friedrich (1991)
10.1016/j.coph.2011.07.006
Revisiting Beta-lactams - PK/PD improves dosing of old antibiotics.
A. Macgowan (2011)
10.1179/JOC.1999.11.5.323
Classification of betalactam antibiotics according to their pharmacodynamics.
P. Periti (1999)
10.1128/AAC.47.6.1862-1866.2003
Clinical Pharmacokinetics of Cefamandole and Ceftazidime Administered by Continuous Intravenous Infusion
J. Berkhout (2003)
10.1046/j.1472-8206.2003.00190.x
Population pharmacokinetics of imipenem in burn patients
É. Dailly (2003)
10.1093/cid/cis856
Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial.
J. Dulhunty (2013)
10.1016/J.AMJMED.2003.07.005
Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis.
S. Harbarth (2003)
The influence of the dosage regimen on the therapeutic effectiveness of penicillin G in experimental lobar pneumonia.
L. Schmidt (1951)
10.1097/00043426-200212000-00006
Continuous Infusion of Ceftazidime in the Empiric Treatment of Febrile Neutropenic Children With Cancer
J. Dalle (2002)
10.1128/AAC.00754-10
Importance of Infusion Volume and Pump Characteristics in Extended Administration of β-Lactam Antibiotics
B. Claus (2010)
10.1128/aac.40.5.1091
Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy.
A. Vinks (1996)
The influence of the dosage regimen on the therapeutic activity of penicillin G.
L. H. Schimdt (1949)
10.1016/J.IJANTIMICAG.2006.02.020
Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients.
M. Rafati (2006)
Letter: Creatinine clearance and age.
Gault Mh (1975)
10.1128/AAC.40.3.691
Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.
A. S. Benko (1996)
On the duration of penicillin action in relation to its concentration in the serum.
H. Eagle (1953)
10.1128/AAC.00521-12
Population Pharmacokinetics of Extended-Infusion Piperacillin-Tazobactam in Hospitalized Patients with Nosocomial Infections
T. Felton (2012)
10.1093/jac/38.1.5
Is continuous infusion of beta-lactam antibiotics worthwhile?--efficacy and pharmacokinetic considerations.
J. Mouton (1996)
10.1128/AAC.00296-09
Identification of Optimal Renal Dosage Adjustments for Traditional and Extended-Infusion Piperacillin-Tazobactam Dosing Regimens in Hospitalized Patients
N. Patel (2009)
10.1016/S0924-8579(01)00329-6
Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia.
D. Nicolau (2001)
10.7326/0003-4819-136-11-200206040-00013
The Commonality of Risk Factors for Nosocomial Colonization and Infection with Antimicrobial-Resistant Staphylococcus aureus, Enterococcus, Gram-Negative Bacilli, Clostridium difficile, and Candida
N. Safdar (2002)
10.1128/AAC.47.6.1991-1994.2003
Stability and Antibacterial Activity of Cefepime during Continuous Infusion
Pål F. Sprauten (2003)
10.1016/j.ijantimicag.2010.06.043
Stability of doripenem, imipenem and meropenem at elevated room temperatures.
R. Keel (2011)
10.1378/chest.115.2.462
Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.
M. Kollef (1999)
10.1007/BF02075257
Influence of dose frequency on the therapeutic efficacies of ciprofloxacin and ceftazidime in experimental Klebsiella pneumoniae pneumonia and septicemia in relation to their bactericidal activities in vitro
R. Roosendaal (2005)
10.1023/B:JOPA.0000029490.76908.0c
A Bayesian Approach to Tracking Patients Having Changing Pharmacokinetic Parameters
D. Bayard (2004)
10.1093/JAC/DKL478
Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study.
J. Roberts (2007)
10.1186/cc4995
Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis
J. Garnacho-Montero (2006)
10.1016/j.ijantimicag.2008.10.005
Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis.
A. Brink (2009)
10.1093/jac/28.6.911
Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion.
J. Mouton (1991)
Human pharmacodynamics of beta-lactams, aminoglycosides and their combination.
G. Drusano (1990)
10.1128/AAC.45.9.2643-2647.2001
Stability and Compatibility of Ceftazidime Administered by Continuous Infusion to Intensive Care Patients
H. Servais (2001)
10.1093/JAC/DKH268
Perioperative pharmacokinetics of cefotaxime in serum and bile during continuous and intermittent infusion in liver transplant patients.
S. Buijk (2004)
10.1111/J.1365-2125.2006.02730.X
Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy.
A. van Zanten (2007)
10.1093/JAC/DKM467
Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection.
R. D. De Jongh (2008)
10.1592/PHCO.22.7.471.33665
Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.
E. M. Grant (2002)
10.1128/AAC.34.12.2307
Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers.
J. Mouton (1990)
10.1128/AAC.38.5.931
Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.
J. Mouton (1994)
10.1097/CCM.0b013e3181a0054d
A systematic review on clinical benefits of continuous administration of &bgr;-lactam antibiotics*
J. Roberts (2009)
10.1016/S0149-2918(00)87978-3
Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion.
D. Burgess (2000)
10.1016/j.clinthera.2008.11.013
Stability of doripenem in vitro in representative infusion solutions and infusion bags.
P. Psathas (2008)
10.1111/j.1469-0691.2005.01238.x
Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance
L. Peterson (2005)
10.2165/00003088-200544020-00005
Pharmacokinetic/Pharmacodynamic Modelling of Antibacterials In Vitro and In Vivo Using Bacterial Growth and Kill Kinetics
J. Mouton (2005)
10.1007/BF01963774
Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin inKlebsiella pneumoniae pneumonia and septicemia in leukopenic rats
R. Roosendaal (2005)
10.1001/archinte.1946.00210360006001
Dynamics of the action of penicillin in experimental animals; observations on mice.
E. Jawetz (1946)
10.1016/j.ijantimicag.2008.09.012
Experience with extended-infusion meropenem in the management of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii.
Donghao Wang (2009)
10.1016/S0149-2918(00)86736-3
Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.
D. Burgess (1999)
10.1007/BF00579709
Stability of aztreonam in a portable pump reservoir used for home intravenous antibiotic treatment (HIVAT)
A. Vinks (2004)
10.1093/JAC/DKL485
Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration.
O. Burkhardt (2007)
Impact of the antibiotic dosage schedule on efficacy in experimental lung infections.
R. Roosendaal (1990)
Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models.
J. Leggett (1990)
10.1093/jac/40.1.125
Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics.
A. Vinks (1997)
10.1007/s15010-008-7274-1
Serum Concentrations of Cefotaxime and its Metabolite Desacetyl-cefotaxime in Infants and Children During Continuous Infusion
R. A. Bertels (2008)
10.2165/11539220-000000000-00000
The Effects of Hypoalbuminaemia on Optimizing Antibacterial Dosing in Critically Ill Patients
M. Ulldemolins (2011)
10.1089/109629602753681104
A pilot study to determine the feasibility of continuous cefazolin infusion.
T. Waltrip (2002)
10.1093/ajhp/46.5.977
Temperature of refrigerated i.v. fluids and admixtures during infusion.
M. Stiles (1989)
10.1128/AAC.36.12.2577
Continuous infusion of beta-lactam antibiotics.
W. Craig (1992)
10.1128/AAC.47.2.541-547.2003
Population Pharmacokinetic Analysis of Nonlinear Behavior of Piperacillin during Intermittent or Continuous Infusion in Patients with Cystic Fibrosis
A. Vinks (2003)
10.1093/JAC/DKL529
Role of ceftazidime dose regimen on the selection of resistant Enterobacter cloacae in the intestinal flora of rats treated for an experimental pulmonary infection.
W. Goessens (2007)
10.1007/s15010-009-8116-5
Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis
Joachim Riethmueller (2009)
10.1093/infdis/158.4.831
Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.
B. Vogelman (1988)
10.1093/jac/dks468
Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia.
A. Muller (2013)
10.1093/JAC/48.2.311
The efficacy of continuous infusion flucloxacillin in home therapy for serious staphylococcal infections and cellulitis.
B. Howden (2001)
10.1056/NEJM199709183371207
Outpatient parenteral antimicrobial-drug therapy.
D. Gilbert (1997)
10.1093/JAC/DKH146
Stability of benzylpenicillin during continuous home intravenous therapy.
J. Vella-Brincat (2004)
10.1128/AAC.00389-08
Continuous Cefazolin Infusion To Treat Bone and Joint Infections: Clinical Efficacy, Feasibility, Safety, and Serum and Bone Concentrations
V. Zeller (2008)
10.1128/AAC.00329-06
Randomized, Open-Label, Comparative Study of Piperacillin-Tazobactam Administered by Continuous Infusion versus Intermittent Infusion for Treatment of Hospitalized Patients with Complicated Intra-Abdominal Infection
W. K. Lau (2006)
10.1592/phco.31.8.767
The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
Raymond J Yost (2011)
10.1345/aph.1G467
Meropenem by Continuous Versus Intermittent Infusion in Ventilator-Associated Pneumonia due to Gram-Negative Bacilli
L. Lorente (2006)
Second place winner of the Conrad Jobst Award in the gold medal paper competition. Increased antibiotic effectiveness in a model of surgical infection through continuous infusion.
W. Naziri (1995)
10.2165/00003495-200059003-00001
Ambulatory Use of Parenteral Antibacterials
J. Leggett (2012)
10.1056/NEJM195303192481201
"Continuous" vs. "discontinuous" therapy with penicillin; the effect of the interval between injections on therapeutic efficacy.
H. Eagle (1953)
10.1128/AAC.39.8.1711
In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa.
J. M. Hyatt (1995)
10.1093/JAC/49.1.121
Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections.
S. Buijk (2002)
10.1046/J.1365-2710.2001.00380.X
Outpatient parenteral antimicrobial therapy (OPAT) for the treatment of osteomyelitis: evaluation of efficacy, tolerance and cost.
L. Bernard (2001)
10.1016/S0022-3476(86)80754-5
Kinetics of antimicrobial activity.
B. Vogelman (1986)
10.1093/JAC/DKG134
Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units.
Nariné Baririan (2003)
10.1016/j.diagmicrobio.2009.03.002
Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections.
G. Patel (2009)
10.1016/S0924-8579(02)00023-7
The application of population pharmacokinetic modeling to individualized antibiotic therapy.
A. Vinks (2002)
10.1007/PL00008370
Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children
I. Rappaz (2000)
10.1128/AAC.00174-09
Continuous versus Intermittent Infusions of Ceftazidime for Treating Exacerbation of Cystic Fibrosis
D. Hubert (2009)
10.1016/S0149-2918(02)80021-2
Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing.
D. Burgess (2002)
10.1093/ajhp/49.11.2761
Stability of ceftazidime (with arginine) and of cefuroxime sodium in infusion-pump reservoirs.
M. Stiles (1992)
10.1128/AAC.30.3.403
Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats.
R. Roosendaal (1986)
10.1016/0002-9343(50)90425-6
Effect of schedule of administration on the therapeutic efficacy of penicillin; importance of the aggregate time penicillin remains at effectively bactericidal levels.
H. Eagle (1950)
10.1016/S0149-2918(04)90051-3
Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis.
J. Kuti (2004)
10.1097/00007691-199408000-00002
Pharmacokinetics of Ceftazidime in Adult Cystic Fibrosis Patients During Continuous Infusion and Ambulatory Treatment at Home
A. Vinks (1994)
10.1086/510590
Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
T. Lodise (2007)
10.1093/JAC/DKM073
Continuous administration of PBP-2- and PBP-3-specific beta-lactams causes higher cytokine responses in murine Pseudomonas aeruginosa and Escherichia coli sepsis.
J. Buijs (2007)
10.1093/JAC/43.4.523
Continuous infusion versus intermittent administration of meropenem in critically ill patients
F. Thalhammer (1999)
10.1093/JAC/43.1.113
The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis.
K. Leder (1999)
10.1016/0002-9343(79)90242-0
A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients.
G. Bodey (1979)
10.1016/j.ijantimicag.2008.10.025
Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion.
L. Lorente (2009)
10.1016/S0140-6736(82)91991-2
EFFECT OF STORAGE OF PENICILLIN-G SOLUTIONS ON SENSITISATION TO PENICILLIN-G AFTER INTRAVENOUS ADMINISTRATION
K. Neftel (1982)
10.1592/PHCO.23.3.291.32110
Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa.
V. Tam (2003)
10.1093/jac/38.6.1055
Bactericidal activity, post antibiotic effect and modified controlled effective regrowth time of meropenem at high concentrations.
K. Bowker (1996)
10.1007/BF02310354
Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia
S. Daenen (2006)
Continuous infusion vs. bolus dosing: implications for beta-lactam antibiotics.
Abdul-Aziz Mohd Hafiz (2012)
10.1093/ajhp/52.1.70
Stability of various antibiotics kept in an insulated pouch during administration via portable infusion pump.
M. Stiles (1995)
10.1093/JAC/DKH536
Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model.
L. Alou (2005)
10.1007/s00134-007-0573-7
Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria
J. Roos (2007)
10.1086/420939
Practice Guidelines for Outpatient Parenteral Antimicrobial Therapy
A. Tice (2004)
10.1093/infdis/159.2.281
Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models.
J. Leggett (1989)
10.1093/JAC/43.2.309
Continuous infusion ceftazidime in intensive care: a randomized controlled trial.
J. Lipman (1999)
10.1097/MCC.0b013e3282e2a98f
Continuous infusion of beta-lactams
J. Mouton (2007)



This paper is referenced by
10.1128/AAC.00862-16
Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients
J. Bradley (2016)
10.1007/s40121-014-0049-3
Population Pharmacokinetics of Cefazolin in Serum and Tissue for Patients with Complicated Skin and Soft Tissue Infections (cSSTI)
Wonhee So (2014)
10.1007/s11894-016-0509-x
Eradication of Helicobacter pylori Infection
E. Marcus (2016)
10.1093/ajhp/zxy035
Ceftazidime stability and pyridine toxicity during continuous i.v. infusion
T. Jones (2019)
10.1007/978-3-319-94424-1_8
Sepsis and septic shock
Anand Kumar (2019)
10.1128/AAC.02624-14
High-Dose Continuous Oxacillin Infusion Results in Achievement of Pharmacokinetics Targets in Critically Ill Patients with Deep Sternal Wound Infections following Cardiac Surgery
N. Nesseler (2014)
10.1055/s-0034-1398387
Clinical management of infections caused by Enterobacteriaceae that express extended-spectrum β-lactamase and AmpC enzymes.
P. Harris (2015)
10.1128/CMR.00022-16
Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory
M. Grupper (2016)
10.1007/s40266-016-0431-9
Meropenem Dosing Based on a Population Pharmacokinetic–Pharmacodynamic Model in Elderly Patients with Infection of the Lower Respiratory Tract
Qing-tao Zhou (2017)
Pharmacokinetics of cefotaxime during continuous and intermittent infusion in critically ill patients *
(2012)
10.1097/CNQ.0b013e3182a10d2f
Trends in Multidrug-Resistant Gram-Negative Bacilli and the Role of Prolonged &bgr;-Lactam Infusion in the Intensive Care Unit
David J. Guervil (2013)
10.1016/J.FARMA.2011.06.013
Piperacilina-tazobactam en perfusión continua o expandida frente a perfusión intermitente
H. A. García (2012)
10.1016/j.jiac.2015.02.001
Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents.
E. Asín-Prieto (2015)
10.1002/phar.1901
Comparison of Rates of Nephrotoxicity Associated with Vancomycin in Combination with Piperacillin‐Tazobactam Administered as an Extended versus Standard Infusion
Mariam Mousavi (2017)
10.1016/j.cca.2017.03.009
Development and validation of a measurement procedure based on ultra-high performance liquid chromatography-tandem mass spectrometry for simultaneous measurement of β-lactam antibiotic concentration in human plasma.
Raül Rigo-Bonnin (2017)
10.1128/AAC.02611-13
Exposure to Ceftobiprole Is Associated with Microbiological Eradication and Clinical Cure in Patients with Nosocomial Pneumonia
A. Muller (2014)
10.1177/0391398819854463
Reply from the authors to ‘In vitro removal of anti-infective agents by a novel cytokine adsorbent system’
C. König (2019)
10.1111/jvp.12122
Intravenous infusion of electrolyte solution changes pharmacokinetics of drugs: pharmacokinetics of ampicillin.
Malka Britzi (2014)
Investigation on gallium maltolate pharmacokinetics and efficacy, as antimicrobial alternative in an equine proliferative enteropathy infection model.
F. Sampieri (2013)
Instructions for use Title Comparison of the Pharmacodynamics of Biapenem in Bronchial Epithelial Lining Fluid in HealthyVolunteers Given Half-Hour and Three-Hour Intravenous Infusions
Eiki Kikuchi (2017)
10.1007/s10096-016-2630-z
Serum concentrations of amoxicillin in neonates during continuous intravenous infusion
A. V. Boekholt (2016)
10.1007/S13546-015-1031-4
Comment réduire les prescriptions d’antibiotiques en réanimation ?
Jean Carlet (2015)
10.1177/0885066617708756
Hospital Length of Stay Among Patients Receiving Intermittent Versus Prolonged Piperacillin/Tazobactam Infusion in the Intensive Care Units
Jeannie D. Chan (2018)
Continuous Infusion of Vancomycin in non-ICU Patients: Why, How and What's the Benefit?
E. Ampe (2013)
PDATE ontinuous infusion of iperacillin / tazobactam in patients ith severe infections : A possible harmacokinetic optimisation ? erfusion continue de pipéracilline / tazobactam chez les patients résentant des infections sévères : une optimisation harmacocinétique possible ?
D. Attivi (2014)
10.14264/uql.2015.515
β-lactam antibiotic pharmacokinetics during continuous venovenous haemofiltration in critically ill patients: continuous infusion versus intermittent bolus administration
Janattul Ain Jamal (2015)
Semantic Scholar Logo Some data provided by SemanticScholar